Compass Pathways just released their data on their phase 2b
https://compasspathways.com/compass-pathways-announces-publication-of-phase-2b-study-of-comp360-psilocybin-therapy-for-treatment-resistant-depression-in-the-new-england-journal-of-medicine/
worth a deeper dive as psilocin starts gaining wider recognition on the back of quality data
- Forums
- ASX - By Stock
- IHL
- Industry news
Industry news, page-676
-
-
- There are more pages in this discussion • 223 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales